Authors: N Bresolin C Zucca A Pecori
Publish Date: 2009/05/20
Volume: 26, Issue: 5, Pages: 563-
Abstract
Patients 18 years with moderate to severe spastic palsy were eligible in this doubleblind randomized study they received eperisone 300 mg/ day or baclofen 60 mg/day for 6 weeks The efficacy evaluations included functional analysis Pedersen’s scale muscular tone joint range of motion 10meter walking time physiological and pathological reflexes and electromyography Hmax/Mmax amplitude ratio and the Wartenberg test Physicians and patients globally assessed treatment efficacyBoth eperisone n=40 and baclofen n=40 significantly improved functionality of lower limbs versus baseline eperisone −91 P001 baclofen −83 P005 but only eperisone improved this parameter in the upper limbs −78 P001 vs −63 P=NS Both drugs reduced muscular tone from week 2 Only eperisone improved the joint range of motion −325 P001 vs −146 P=NS Both treatments reduced the 10meter walking time eperisone −202 P001 baclofen −240 P001 this effect was evident at week 2 with eperisone only Both drugs improved reflexes Eperisone and baclofen decreased the Hmax/Mmax amplitude ratio eperisone −300 baclofen −186 P001 for both Eperisone increased the number of leg oscillations at the Wartenberg test P005 while baclofen increased the velocity of leg falling P001 For tolerability no differences were observed between eperisone and baclofen in any parameters Eperisone was judged as “good“ by a higher number of physicians and patients than baclofen Eighteen adverse events most of mild intensity were reported with eperisone and 27 with baclofen
Keywords: